News | February 05, 2024
RPG Life Sciences posts Q3 FY24 PAT at Rs. 26.46 Cr
RPG Life Sciences Limited has reported total income of Rs. 155.62 crores during the period ended December 31, 2023
RPG Life Sciences Limited has reported total income of Rs. 155.62 crores during the period ended December 31, 2023
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
The company will be preferred business partner for VPPL in terms of sourcing and supplying key raw materials
Astec LifeSciences has reported total income of Rs. 51.70 crores during the period ended December 31, 2023
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
Subscribe To Our Newsletter & Stay Updated
